- Edwards, John;
- Schwartz, Michael;
- Schmidt, Clint;
- Sobel, Jack;
- Nyirjesy, Paul;
- Schodel, Florian;
- Marchus, Erica;
- Lizakowski, Mary;
- DeMontigny, Elizabeth;
- Hoeg, Jesse;
- Holmberg, Tuomas;
- Cooke, M;
- Hoover, Keila;
- Edwards, Lance;
- Jacobs, Mark;
- Sussman, Steven;
- Augenbraun, Michael;
- Drusano, Michael;
- Hennessey, John;
- Yeaman, Michael;
- Filler, Scott;
- Ibrahim, Ashraf
BACKGROUND: Recurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC. METHODS: This exploratory randomized, double-blind, placebo-controlled trial evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of RVVC. RESULTS: The study in 188 women with RVVC (n = 178 evaluable) showed that 1 intramuscular dose of NDV-3A was safe and generated rapid and robust B- and T-cell immune responses. Post hoc exploratory analyses revealed a statistically significant increase in the percentage of symptom-free patients at 12 months after vaccination (42% vaccinated vs 22% placebo; P = .03) and a doubling in median time to first symptomatic episode (210 days vaccinated vs 105 days placebo) for the subset of patients aged <40 years (n = 137). The analysis of evaluable patients, which combined patients aged <40 years (77%) and ≥40 years (23%), trended toward a positive impact of NDV-3A versus placebo (P = .099). CONCLUSIONS: In this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women with RVVC was safe and highly immunogenic and reduced the frequency of symptomatic episodes of vulvovaginal candidiasis for up to 12 months in women aged <40 years. These results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of RVVC. CLINICAL TRIALS REGISTRATION: NCT01926028.